Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort
Journal of Parkinson’s Disease · 23.01.2024 · 14 (1) · 209-219
DOI: 10.3233/jpd-230201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 04.01.2024. Verfasst von Matthieu Béreau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, CHU Besançon, Besançon, France. Hauptthemen laut MEDLINE: Parkinson Disease, Terminal Care. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
There are currently no recommendations on the therapeutic management of Parkinson’s disease (PD) patients at the end of life.
Objective
To describe a cohort of patients with PD who benefited from continuous subcutaneous apomorphine infusion (CSAI) initiation at the end of their life as comfort care.
Methods
This real-life cohort includes 14 PD patients, who benefited from 24-h, low-dose CSAI (0.5–3 mg/h) in the context of terminal care. Patient’s comfort (pain, rigidity, and/or ability to communicate) and occurrence of CSAI-related side-effects (nausea/vomiting, cutaneous and behavioral manifestations) were evaluated based on medical records.
Results
All patients (age 62–94 years, disease duration 2–32 years) presented with late-stage PD and a compromised oral route. Treatment lasted from a few hours to 39 days. CSAI led to substantial functional improvement, with a good safety profile. Overall clinical comfort was deemed improved by the medical team, the patient, and/or caregivers.
Conclusions
CSAI might be a promising approach in PD terminal care, as it reduces motor symptoms and overall discomfort, with an apparent good safety profile. Use of the apomorphine pen, sublingual film or a classic syringe pump might be considered when apomorphine pumps are not available. Larger observational cohorts and randomized controlled trials are needed to establish the efficacy and tolerability of apomorphine in the context of terminal care and more broadly, in an advance care planning perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, CHU Besançon, Besançon, France.
- Université de Franche-Comté, UR LINC, Besançon, France.
- Mobile Palliative Care Team, CHU Besançon, Besançon, France.
- Inserm CIC 1431, CHU Besançon, Besançon, France.
- Department of Pharmacy, University Hospital of Besançon, Besançon, France.
- Palliative care unit, Clinique des Augustines, Malestroit, France.
Zitieren
APA
Béreau, M., Giffard, M., Clairet, A. L., Degenne, G., Tatu, L., Richfield, E., Magnin, E., Vérin, M., & Auffret, M. (2024). Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort. Journal of Parkinson’s Disease, 14(1), 209-219. https://doi.org/10.3233/jpd-230201
Vancouver
Béreau M, Giffard M, Clairet AL, Degenne G, Tatu L, Richfield E, et al. Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort. Journal of Parkinson’s Disease. 2024;14(1):209-219. doi:10.3233/jpd-230201
BibTeX
@article{Breau2024,
author = {Béreau, Matthieu and Giffard, Mathilde and Clairet, Anne-Laure and Degenne, Guillaume and Tatu, Laurent and Richfield, Edward and Magnin, Eloi and Vérin, Marc and Auffret, Manon},
title = {Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort},
journal = {Journal of Parkinson’s Disease},
year = {2024},
volume = {14},
number = {1},
pages = {209--219},
doi = {10.3233/jpd-230201}
}
EUVIMED